Balaxi Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, during its Board Meeting held on May 28, 2026. On a standalone basis, the company reported a total income of ₹2,360.65 Lakhs for the quarter, compared to ₹2,621.74 Lakhs in the previous quarter and ₹996.98 Lakhs in the corresponding quarter of the previous year. The net profit for the quarter stood at ₹15.81 Lakhs, against ₹153.06 Lakhs in the previous quarter and a loss of ₹117.85 Lakhs in the same quarter last year.

Balaxi Pharmaceuticals Limited is a specialized wholesale company with a business model focused on pharmaceutical formulations. Recently, the company received the manufacturing license for its first pharmaceutical formulation plant at Jadcherla, Hyderabad, on May 23, 2026, following a successful inspection by CDSCO. The company is preparing for the commercialization of Paracetamol Tablet 500mg and Piroxicam Capsule 20mg and is initiating processes for 40 additional products, while also moving toward obtaining WHO-GMP certification for the facility to bolster its manufacturing capabilities and future growth opportunities.